Wave Health PRO-WAVE1 Study Published In “ESMO Real World Data and Digital Oncology” Journal
“Feasibility of Wave Health to monitor electronic patient-reported outcomes (ePROs) in prostate cancer patients” presents further findings
Highlights
Wave Health app achieved 93.3% ePRO compliance in collecting ePROs for inpatients with prostate cancer.
Most patients (80%) completed ePROs without needing assistance.
Most health care providers (97.6%) and patients (95.4%) found the platform useful.
High compliance rates were observed regardless of age, education, or tech confidence.
Background
Benefits of electronic patient-reported outcomes (ePROs) are well established, but concerns exist around their applicability in certain cancer patient populations. This multicenter study aimed to evaluate the feasibility and compliance of a novel platform, Wave Health, to automate the collection of ePROs among patients undergoing systemic treatment for prostate cancer.
Patients and Methods
The study was conducted across eight Spanish hospitals where prostate cancer patients able to use smartphones were asked to download the Wave Health app and fill out different ePRO questionnaires weekly for 12 weeks. The primary outcome was compliance with questionnaire completion.
Spain Study Background - Full study article is available here.
Results
Eighty-seven patients were enrolled (48% aged >70 years; 48% >high school educated). The compliance rate using the app was 93.3% to complete 19 scheduled ePRO questionnaires during their participation, and the acceptance rate was 94.3%. Most patients described the app as intuitive and completed most ePROs (>80%) ‘without help’, even though 28.7% reported a lack of technology confidence. The mean Cancer Health Literacy Test-30-Spanish (CHLT-30-DKspa) score increased from 22.3 at baseline to 23.2 at week 12. Fatigue, weakness, and poor sleep were the most common symptoms reported by patients. Most health care providers (97.6%) rated the platform as ‘very useful,’ ‘useful,’ or ‘somewhat useful.’
Conclusion
This study demonstrated that ePRO collection via the Wave Health platform is feasible, with high rates of compliance, acceptance, and satisfaction among prostate cancer patients under systemic treatment regardless of age, education, or level of tech confidence, and that the app is perceived as useful among health care providers.
Download the full ESMO article here.
About ESMO
ESMO Real-World Data and Digital Oncology is a peer-reviewed, open-access journal by the European Society for Medical Oncology (ESMO) that publishes innovative research on using real-world data and digital technologies to advance cancer care. The journal aims to provide actionable insights for physicians and health systems by publishing studies on data science, clinical informatics, decision support systems, and mobile health applications.
About Wave Health
Born from a personal cancer experience, Wave Health is a trusted, comprehensive digital health platform to transform the management and understanding of chronic conditions of large volume patient populations. Comprised of patient app and care portal, the platform efficiently collects, manages, and analyses missing patient reported data from outside the clinical setting (real-time and over the course of treatment). The platform generates actionable insights to drive patient engagement and adherence, and to help medical teams manage individual treatments including identifying emerging risks. For more information, please visit www.wavehealth.app.
The Wave Health product has been created by TTI. The Spain study was financially supported by Bayer AG. In the UK, Bayer has partnered with TTI as marketing agent for the prostate cancer version of Wave Health and is not responsible for the content or function of the product in any way.
Source
Gomez Mediavilla, B, et al. “Feasibility of Wave Health to monitor electronic patient-reported outcomes (ePROs) in prostate cancer patients”. ESMO Real World Data and Digital Oncology, Vol 10, Dec. 2025.